Takeda Pharmaceutical Company Limited (TYO:4502)
Japan
· Delayed Price · Currency is JPY 5,617.00
-70.00 (-1.23%)
At close: Mar 9, 2026
TYO:4502 Revenue
Takeda Pharmaceutical Company had revenue of 1.19T JPY in the quarter ending December 31, 2025, with 4.16% growth. This brings the company's revenue in the last twelve months to 4.46T, down -2.50% year-over-year. In the fiscal year ending March 31, 2025, Takeda Pharmaceutical Company had annual revenue of 4.58T with 7.45% growth.
Revenue (ttm)
4,464.58B
Revenue Growth
-2.50%
P/S Ratio
1.99
Revenue / Employee
94.08M
Employees
47,455
Market Cap
8,873.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4,581.55B | 317.79B | 7.45% |
| Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
| Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
| Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
| Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shionogi & | 465.38B |
| Eisai | 808.19B |
| Sumitomo Pharma | 453.40B |
| Hisamitsu Pharmaceutical Co. | 159.27B |
| Nippon Shinyaku | 166.05B |
| Toho Holdings | 1,539.60B |
| Tsumura & Co. | 189.50B |
| Sawai Group Holdings | 200.68B |
Takeda Pharmaceutical Company News
- 4 days ago - Takeda Pharmaceutical Company Limited (TAK) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 5 days ago - Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - Benzinga
- 7 days ago - Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera - Business Wire
- 18 days ago - Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis - Business Wire
- 27 days ago - Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market - Benzinga
- 27 days ago - U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda's Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1 - Business Wire
- 4 weeks ago - Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery - Benzinga
- 4 weeks ago - Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery - Benzinga